A5047804011- Extracellular vesicles in disease
- Prostate Cancer Treatment and Research
- Renal and related cancers
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- RNA modifications and cancer
- RNA Interference and Gene Delivery
- Estrogen and related hormone effects
- MicroRNA in disease regulation
- Cancer Immunotherapy and Biomarkers
- Telomeres, Telomerase, and Senescence
- Mass Spectrometry Techniques and Applications
- Cancer-related molecular mechanisms research
- Advanced biosensing and bioanalysis techniques
- Nanoplatforms for cancer theranostics
- Cancer Genomics and Diagnostics
- Mechanisms of cancer metastasis
- Nanoparticle-Based Drug Delivery
- Health, Medicine and Society
- Advanced Radiotherapy Techniques
- Enhanced Recovery After Surgery
- Enzyme Structure and Function
- Health Systems, Economic Evaluations, Quality of Life
- Gastroesophageal reflux and treatments
- Parkinson's Disease and Spinal Disorders
The University of Texas MD Anderson Cancer Center
2015-2024
Molecular Oncology (United States)
2017
Houston Methodist
2013-2015
Magna Graecia University
2013
Cancer is a complex disease that usually requires several treatment modalities. A multifunctional nanotherapeutic system designed, incorporating small interfering RNA (siRNA) and gold nanorods (Au NRs) for photothermal therapy. Surface‐engineered Au NRs with polyethylenimine are synthesized using layer‐by‐layer assembly siRNA absorbed on the surface. The efficiently delivered into breast cancer cells, resulting in subsequent gene silencing. Cells then irradiated near‐infrared (NIR) light,...
Abstract Purpose: Radium-223 prolongs survival in a fraction of men with bone metastatic prostate cancer (PCa). However, there are no markers for monitoring response and resistance to treatment. Exosomes mediators intercellular communication may reflect the microenvironment We performed molecular profiling exosomes compared profile patients favorable unfavorable overall survival. Experimental Design: exosomal transcriptome analysis plasma derived from our preclinical models (MDA-PCa 118b...
<p>Effects of TKIs on blood vessels in RENCA VHL- bone and lung tumors. A) Visual representation the experimental approach. B,C) Bone tumors: representative pictures captured at confocal microscope quantification vessel area tumor (green, GFP), nuclei (blue, DAPI); (yellow, endomucin; red, laminin); dotted line, edge; single channel endomucin is shown. A % shown, mean + SEM, n=3-4/group; Bar, 100 µm. D,E) Lung (C) (red, CD31); CD31 µm P values by one-way ANOVA with Tukey’s HSD post hoc...
<p>Blood vessel marker expression in bone marrow and tumors. A, B) Detection of (A) tumor (B) blood vessels by confocal acquisition; blue, DAPI; yellow, endomucin; red, laminin; green, GFP; white boxes, magnifications reported on right panels; arrowhead, lack physical overlap between markers; C) Immunofluorescence detection VHL- RENCA tumors microscopy; D) Quantification area inside outside based laminin (red) endomucin (yellow) signal, mean + SEM, n=3-4/group; with only one expressed....
<p>TKIs’ effect on blood vessels and immune infiltrate in LVRCC67 model. A) Representative images of bone tumors captured by confocal microscope; tumor cells (green, PAX8), CD8+ (yellow), (CD31, red); nuclei (blue, DAPI); dotted line, edge; B) Quantification vessel area, number over area cell distribution, mean + SEM, n=3/group. P values one-way ANOVA with Tukey’s HSD post hoc test; p < 0.01 = **. Bar, 100 µm. BV-blood vessels; V-vehicle, A-axitinib, C-cabozantinib, L-lenvatinib;...
<p>Analysis of CD8+ cell infiltration at baseline in bone tumors and description COMET analysis. A) Representative images captured by confocal microscope quantification number; tumor (green, GFP), cells (yellow), blood vessels (laminin, red), nuclei (blue, DAPI); dashed line, edge; mean + SEM, n=3/group; dotted lines. B) Spatial definition lines were draw 25 µm distance from the edge, that represents interface. C) A % is shown, n=3/group. D) Visual representation experimental design...
<p>Efficacy of TKIs in VHL- RENCA tumors treated at day 14 post-tumor injection. A) Visual representation the experimental approach. B) Representative images bioluminescence signal bones followed by quantification photon flux, mean + SEM, n=8-16/group; P values one-way ANOVA with Tukey’s HSD post hoc test; p < 0.0001 = ****.</p>
<p>Cross-sectional slices of tibiae with VHL- RENCA after TKIs treatment. Representative images bone tumors post- treatment, obtained by confocal microscope: green, GFP; yellow, endomucin; red, laminin; blue, DAPI. Bar, 100 µm. Endo-endomucin; Lam-laminin.</p>
<p>Osteoclast recruitment and bone disruption. A) RENCA VHL- cells (green, GFP); osteoclasts (red, TRAP); nuclei (blue, DAPI); white arrowhead, TRAP+ cells. Bar, 50 µm; B) UM-RC-3 µm. Images captured by confocal microscope. TRAP-tartrate-resistant acid phosphatase. White rectangle, (i); magnification.</p>
<p>In vivo efficacy of TKIs in VHL- RENCA model over 20 days. A, B) Response to bone (A) and lung (B) tumors detected by bioluminescence, mean + SEM, n = 8 16/group.</p>
<p>Effects of TKI withdrawal on vascularization and immune cell infiltration in bone tumors. A) Representative images tumors 12 days following TKIs; tumor (green, GFP), blood vessels (red, laminin) nuclei (blue, DAPI) CD8+ cells (yellow) captured by confocal microscope quantifications are shown (B); mean + SEM, n=3/group. Bar, 100 µm. BV – vessels. Lam-laminin; IN-inner region.</p>
<p>Blood vessel distance analysis in bone tumors. (1) Representative images of (VHL- RENCA) tumors captured by confocal microscope; tumor cells (green, GFP); blood vessels (yellow, endomucin; red, laminin), nuclei (blue, DAPI); (2) single endomucin channel and examples measures (yellow bar lines) calculated Fig. 3 D, F; dotted line, the area tumor. Endo-endomucin; Lam-laminin.</p>
<p>CD8+ cell infiltration of lung tumors at baseline and following TKI administration. A) Representative images CD8+ cells in captured by confocal microscope (no treatment), day 7, 14 21 post-tumor injection; tumor (green, GFP), (yellow), blood vessels (CD31, red), nuclei (blue, DAPI); dotted line, edge. B) A quantification number their distribution over time is shown, mean + SEM, n=3/group. C) post-TKI treatment; GFP); (red, CD31), D) number, area shown; n=6-8/group. P values one-way...
<p>Effects of TKIs on bone tumors in UM-RC-3 model. A) Visual representation the experimental approach. B, C) Neo-angiogenesis tibiae (B) and quantification (C) area occupied by blood vessels tumors; representative images obtained confocal microscope, blue, DAPI; green, GFP; yellow, endomucin; red, laminin; dotted line, tumor edge; mean + SEM, n=4/group. P values one-way ANOVA with Tukey’s HSD post hoc test; p < 0.05 = *, 0.01 **. Bar, 100 µm. Endo/Endom-endomucin; Lam-laminin;...
Prostate cancer is a major cause of morbidity and mortality in men worldwide. Androgen deprivation therapy (ADT) has proven effective early-stage androgen-sensitive disease, but prostate gradually develops into an androgen-resistant metastatic state the vast majority patients. According to our oncogene-induced model for development, senescence tumor progression barrier. However, whether implicated highly aggressive castration-resistant (CRPC) remains poorly addressed.Androgen-dependent...
This integrative multistage study was aimed to identify circulating microRNAs (miRNAs) as prognostic biomarkers and investigate the treatment target for early-stage non-small cell lung cancer (NSCLC) patients. In stage I-II NSCLC patients, we screened validated miRNA ratio signatures predictive of prognosis in serum. tumor, found that expression miR-150 identified also associated with survival. Increased promoted proliferation migration vice versa. Specific mRNA cleavage sites targeted by...
Expression of the TUSC2 tumor-suppressor gene in TUSC2-deficient NSCLC cells decreased PD-L1 expression and inhibited mTOR activity. Overexpressing or treatment with rapamycin resulted similar inhibition expression. Both p70 SK6 phosphorylation, suggesting that share same target. Microarray mRNA analysis using TUSC2-inducible H1299 showed genes negatively regulate pathway were significantly upregulated by compared control. The presence IFN-γ increased lung cancer cell lines, but...
Abstract Clear cell renal carcinoma (ccRCC) is the most prevalent kidney neoplasm; bone metastasis (BM) develops in 35-40% of metastatic patients and results substantial morbidity mortality, as well medical costs. A key feature ccRCC loss function von Hippel–Lindau (VHL) protein, which enhances angiogenesis via vascular endothelial growth factor release. Consequently, anti-angiogenic tyrosine kinase inhibitors (TKIs) emerged a treatment for ccRCC. However, limited data about their efficacy...
Therapeutic guidelines indicate prostacyclin as the first line of treatment in inflammation and vascular diseases. Prostacyclins prevent formation platelet plug involved primary hemostasis by inhibiting activation and, combined with thromboxane, are effective vasodilators damage. Trans-Atlantic Inter-Society Consensus Document on Management Peripheral Arterial Disease II indicates prostacyclins; particular, Iloprost, therapeutic option for treating peripheral arterial disease. However,...
// Emanuela Gentile 1 , Taro Oba Jing Lin Ruping Shao Feng Meng Xiaobo Cao Heather Y. 2 Majidi Mourad Apar Pataer Veerabhadran Baladandayuthapani Dong Cai 3 Jack A. Roth and Ji Section of Thoracic Molecular Oncology, Department & Cardiovascular Surgery, The University Texas MD Anderson Cancer Center, Houston, TX 77030, United States Biostatistics, Physics, 77004, Correspondence to: Gentile, email: egentile@mdanderson.org Keywords: delivery systems, cationic nanoparticles, RNAi, lung...
<div>Abstract<p>Clear cell renal carcinoma (ccRCC) is the most prevalent kidney neoplasm; bone metastasis (BM) develops in 35% to 40% of metastatic patients and results substantial morbidity mortality, as well medical costs. A key feature ccRCC loss function von Hippel–Lindau protein, which enhances angiogenesis via vascular endothelial growth factor release. Consequently, antiangiogenic tyrosine kinase inhibitors (TKI) emerged a treatment for ccRCC. However, limited data about...
<p>Efficacy of TKIs in VHL- RENCA tumors treated at day 14 post-tumor injection. A) Visual representation the experimental approach. B) Representative images bioluminescence signal bones followed by quantification photon flux, mean + SEM, n=8-16/group; P values one-way ANOVA with Tukey’s HSD post hoc test; p < 0.0001 = ****.</p>